TIDMAPH

RNS Number : 1747T

Alliance Pharma PLC

22 November 2021

22 November 2021

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Director's Dealing

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that it has today received notice that Peter Butterfield, Chief Executive Officer of Alliance, exercised options over 500,000 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") under the Company's Share Option Plans at an exercise price of 47.5 pence per share (granted in 2016). These were net settled by the Company of which 230,583 shares were not issued as a result of the net settlement.

As such, following this exercise, 269,417 Ordinary Shares were sold at a price of 102.5p pence per share, in part to satisfy costs and tax liabilities. In accordance with the Group's share retention policy, following this transaction, Mr Butterfield has a beneficial interest in 442,104 Ordinary Shares and 1,750,000 vested but unexercised share options. Mr Butterfield continues to maintain his 200% of salary holding requirement.

The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                              Peter Butterfield 
     --------------------------------  -------------------------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------------------------ 
 a)   Position/status                   Chief Executive Officer 
     --------------------------------  -------------------------------------------------- 
 b)   Initial notification              Initial Notification 
       /Amendment 
     --------------------------------  -------------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------------------------ 
 a)   Name                              ALLIANCE PHARMA PLC 
     --------------------------------  -------------------------------------------------- 
 b)   Legal Entity                      213800RYIWZA4Q5WPZ13 
       Identifier 
     --------------------------------  -------------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------------------------ 
 a)   Description of                    Ordinary shares of 1 pence each 
       the financial 
       instrument, type 
       of instrument                     GB0031030819 
       Identification 
       code 
     --------------------------------  -------------------------------------------------- 
 b)   Nature of the                          a) Exercise of options 
       transaction                            b) Sale of Ordinary Shares 
     --------------------------------  -------------------------------------------------- 
 c)   Currency                          GBP 
     --------------------------------  -------------------------------------------------- 
 d)   Price(s) and                      Price(s)                          Volume(s) 
       volume(s) 
     --------------------------------  --------------------------------  ---------------- 
                                             a) 47.5 pence                a) 500,000 
                                              b) 102.5 pence               b) 269,417 
     --------------------------------  --------------------------------  ---------------- 
 
 e)   Aggregated information            a) 500,000 options over Ordinary Shares, 
       - Aggregated                      at an exercise price of 47.5 pence per Share. 
       volume 
       - Price                           b) 269,417 Ordinary Shares, sold at an average 
       - Aggregated                      price of 102.5 pence per Ordinary Share, 
       total                             totalling GBP276,152 
     --------------------------------  -------------------------------------------------- 
 f)   Date of the transaction(s)        19 November 2021 
     --------------------------------  -------------------------------------------------- 
 g)   Place of the                      London Stock Exchange, AIM 
       transaction 
     --------------------------------  --------------------------------------------------

For further information:

 
 Alliance Pharma plc                          + 44 (0)1249 466966 
 Peter Butterfield, Chief Executive 
  Officer 
 Andrew Franklin, Chief Financial Officer 
 www.alliancepharma.co.uk 
 Buchanan                                    + 44 (0)20 7466 5000 
 Mark Court / Sophie Wills / Hannah 
  Ratcliff 
 
 Numis Securities Limited                    + 44 (0)20 7260 1000 
 Nominated Adviser: Freddie Barnfield 
  / Duncan Monteith 
 Corporate Broking: James Black 
 
 
 Investec Bank plc                  + 44 (0) 20 7597 5970 
 Corporate Finance: Daniel Adams 
 Corporate Broking: Patrick Robb

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHPPGMPGUPGGQP

(END) Dow Jones Newswires

November 22, 2021 11:29 ET (16:29 GMT)

Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Alliance Pharma Charts.
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Alliance Pharma Charts.